{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:15:53Z","timestamp":1788218153473,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CIHR Doctoral Award: Frederick Banting and Charles Best Canadian Graduate Scholarship"},{"name":"Canada Research Chair in Drug Policy and Substance Use"},{"DOI":"10.13039\/100014608","name":"St. Michael\u2019s Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People who inject drugs (PWID) are at increased risk of infective endocarditis (IE). While opioid injection is a major risk factor for IE, the risk associated with specific prescription opioids, such as hydromorphone, remains unclear and is inconsistently reported, despite a hypothesized pathway whereby the insolubility of controlled-releaseformulations may promote injection equipment reuse and bacterial contamination. Therefore, we estimated and compared the 1-year incidence rates of IE among PWID reporting injection of hydromorphone versus non-hydromorphone opioid medications and versus other opioids\/drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Baseline questionnaire data on PWID in the Ontario Integrated Supervised Injection Services cohort (November 2018\u2013March 2020) were linked to health administrative databases. IE incidence was calculated over 1-year post-baseline. Participants were followed until first of IE, death, or 1-year censoring. Exposure was self-reported recent (past 6\u00a0months) injection of: hydromorphone, non-hydromorphone opioid medications of interest, or other opioids\/drugs. Cox regression estimated associations, adjusting for age, gender, ethnicity, injection drug use, and prior injection-related infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 514 participants included, 191 reported recent injection of hydromorphone, 32 non-hydromorphone opioid medications of interest, and 291 other opioids\/drugs. IE incidence rates were low across groups: 1.6, 3.3, and 1.8 per 100 person-years. Adjusted hazard ratio comparing recent hydromorphone injection versus non-hydromorphone opioid medications of interest was 0.64 (95% confidence interval (CI) 0.06\u20136.53); versus other opioids\/drugs was 0.82 (95% CI 0.19\u20133.51).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this cohort of PWID, no clear association was found between hydromorphone injection and IE when compared to non-hydromorphone opioid medications or to other opioids\/drugs. Due to low event rates and the resulting wide CIs, the findings are limited by low statistical precision. Further research with larger cohorts is warranted to quantify IE risk of specific injected drugs among PWID.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01479-x","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:07:29Z","timestamp":1781914049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent hydromorphone injection and risk of incident infective endocarditis among people who inject drugs in Toronto, Canada: a cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Nicholas","family":"Bakewell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Bouck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00eb R.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Upham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina G.","family":"Birck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano S.","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Neville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Werb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"6","key":"1479_CR1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2468-1253(19)30085-8","volume":"4","author":"A Trickey","year":"2019","unstructured":"Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019;4(6):435\u201344.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1479_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00057-8","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023. https:\/\/doi.org\/10.1016\/S2214-109X(23)00057-8.","journal-title":"Lancet Glob Health"},{"issue":"Supplement_5","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1093\/infdis\/jiaa432","volume":"222","author":"A Levitt","year":"2020","unstructured":"Levitt A, Mermin J, Jones CM, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. J Infect Dis. 2020;222(Supplement_5):S213\u20137.","journal-title":"J Infect Dis"},{"issue":"3","key":"1479_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/0706743716632503","volume":"61","author":"\u00c9 Roy","year":"2016","unstructured":"Roy \u00c9, Arruda N, Bruneau J, Jutras-Aswad D. Epidemiology of injection drug use: new trends and prominent issues. Can J Psychiatry. 2016;61(3):136\u201344.","journal-title":"Can J Psychiatry"},{"issue":"1","key":"1479_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2105\/AJPH.2019.305379","volume":"110","author":"B Jacka","year":"2020","unstructured":"Jacka B, Larney S, Degenhardt L, Janjua N, H\u00f8j S, Krajden M, et al. Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada. Am J Public Health. 2020;110(1):45\u201350.","journal-title":"Am J Public Health"},{"key":"1479_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104197","volume":"141","author":"M MacDonald","year":"2023","unstructured":"MacDonald M, Cheng C, Wang T, McCormack D, Kolla G, Cahill TM, et al. Trends in varying modes of drug use in opioid toxicity deaths in Ontario from 2017 to 2021. Int J Drug Policy. 2023;141:104197.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1479_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12954-020-00378-z","volume":"17","author":"M Shah","year":"2020","unstructured":"Shah M, Wong R, Ball L, Puka K, Tan C, Shojaei E, et al. Risk factors of infective endocarditis in persons who inject drugs. Harm Reduct J. 2020;17(1):35.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1479_CR8","doi-asserted-by":"publisher","first-page":"E93","DOI":"10.1503\/cmaj.180694","volume":"191","author":"MA Weir","year":"2019","unstructured":"Weir MA, Slater J, Jandoc R, Koivu S, Garg AX, Silverman M. The risk of infective endocarditis among people who inject drugs: a retrospective, population-based time series analysis. CMAJ. 2019;191(4):E93\u20139.","journal-title":"CMAJ"},{"issue":"10","key":"1479_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/add.16257","volume":"118","author":"TD Brothers","year":"2023","unstructured":"Brothers TD, Bonn M, Lewer D, Comeau E, Kim I, Webster D, et al. Social and structural determinants of injection drug use-associated bacterial and fungal infections: a qualitative systematic review and thematic synthesis. Addiction. 2023;118(10):1853\u201377.","journal-title":"Addiction"},{"issue":"3","key":"1479_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.idc.2020.06.004","volume":"34","author":"A Schranz","year":"2020","unstructured":"Schranz A, Barocas JA. Infective endocarditis in persons who use drugs: epidemiology, current management, and emerging treatments. Infect Dis Clin N Am. 2020;34(3):479\u201393.","journal-title":"Infect Dis Clin N Am"},{"issue":"3","key":"1479_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw157","volume":"3","author":"AG Wurcel","year":"2016","unstructured":"Wurcel AG, Anderson JE, Chui KK, Skinner S, Knox TA, Snydman DR, et al. Increasing infectious endocarditis admissions among young people who inject drugs. Open Forum Infect Dis. 2016;3(3):ofw157.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"1479_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11524-021-00547-w","volume":"98","author":"AI Scheim","year":"2021","unstructured":"Scheim AI, Sniderman R, Wang R, Bouck Z, McLean E, Mason K, et al. The Ontario integrated supervised injection services cohort study of people who inject drugs in Toronto, Canada (OiSIS-Toronto): cohort profile. J Urban Health. 2021;98(4):538\u201350.","journal-title":"J Urban Health"},{"issue":"4","key":"1479_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1473-3099(19)30705-4","volume":"20","author":"M Silverman","year":"2020","unstructured":"Silverman M, Slater J, Jandoc R, Koivu S, Garg AX, Weir MA. Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study. Lancet Infect Dis. 2020;20(4):487\u201397.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1479_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219777","volume":"14","author":"KJ Kasper","year":"2019","unstructured":"Kasper KJ, Manoharan I, Hallam B, Coleman CE, Koivu SL, Weir MA, et al. A controlled-release oral opioid supports S. aureus survival in injection drug preparation equipment and may increase bacteremia and endocarditis risk. PLoS ONE. 2019;14(8):e0219777.","journal-title":"PLoS ONE"},{"issue":"1-2","key":"1479_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2012.05.018","volume":"126","author":"E Roy","year":"2012","unstructured":"Roy E, Arruda N, Leclerc P, Haley N, Bruneau J, Boivin JF. Injection of drug residue as a potential risk factor for HCV acquisition among Montr\u00e9al young injection drug users. Drug Alcohol Depend. 2012;126(1\u20132):246\u201350.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"1479_CR16","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1097\/QAI.0000000000002062","volume":"81","author":"LJ Ball","year":"2019","unstructured":"Ball LJ, Puka K, Speechley M, Wong R, Hallam B, Wiener JC, et al. Sharing of injection drug preparation equipment is associated with HIV infection: a cross-sectional study. J Acquir Immune Defic Syndr. 2019;81(4):e99\u2013103.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1479_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-023-00788-9","volume":"20","author":"AC Tricco","year":"2023","unstructured":"Tricco AC, Parker A, Hezam A, Nincic V, Yazdi F, Lai Y, et al. Controlled-release hydromorphone and risk of infection in adults: a systematic review. Harm Reduct J. 2023;20(1):1\u20138.","journal-title":"Harm Reduct J"},{"issue":"2","key":"1479_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/EDE.0000000000001443","volume":"33","author":"Z Bouck","year":"2022","unstructured":"Bouck Z, Tricco AC, Rosella LC, Ling V, Gomes T, Tadrous M, et al. Validation of self-reported opioid agonist treatment among people who inject drugs using prescription dispensation records. Epidemiology. 2022;33(2):287\u201394.","journal-title":"Epidemiology"},{"issue":"4","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/ADM.0000000000000928","volume":"16","author":"T Gomes","year":"2022","unstructured":"Gomes T, Kitchen SA, Tailor L, Men S, Murray R, Bayoumi AM, et al. Trends in hospitalizations for serious infections among people with opioid use disorder in Ontario. Canada J Addict Med. 2022;16(4):433\u20139.","journal-title":"Canada J Addict Med"},{"issue":"7","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"e1649","DOI":"10.1093\/cid\/ciaa1278","volume":"73","author":"DP Serota","year":"2021","unstructured":"Serota DP, Bartholomew TS, Tookes HE. Evaluating differences in opioid and stimulant use-associated infectious disease hospitalizations in Florida, 2016-2017. Clin Infect Dis. 2021;73(7):e1649\u201357.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1479_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"1479_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266663","volume":"17","author":"J Lim","year":"2022","unstructured":"Lim J, Pavalagantharajah S, Verschoor CP, Lentz E, Loeb M, Levine M, et al. Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs. PLoS ONE. 2022;17(4):e0266663.","journal-title":"PLoS ONE"},{"issue":"10","key":"1479_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885.","journal-title":"PLoS Med"},{"key":"1479_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.drugpo.2017.05.005","volume":"46","author":"VD Hope","year":"2017","unstructured":"Hope VD, Iversen J, Cullen KJ, Parry JV, Maher L, Nucbe F. Injection into the jugular vein among people who inject drugs in the United Kingdom: prevalence, associated factors and harms. Int J Drug Policy. 2017;46:28\u201333.","journal-title":"Int J Drug Policy"},{"key":"1479_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ijcard.2016.09.030","volume":"224","author":"C Tan","year":"2016","unstructured":"Tan C, Hansen M, Cohen G, Boyle K, Daneman N, Adhikari NK. Accuracy of administrative data for identification of patients with infective endocarditis. Int J Cardiol. 2016;224:162\u20134.","journal-title":"Int J Cardiol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01479-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01479-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01479-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:41:33Z","timestamp":1788216093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01479-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01479-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval was obtained from the Unity Health Toronto Research Ethics Board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}